Retatrutide in the UK: How People Are Accessing It and the Risks

How people are getting retatrutide is a question gaining traction in the UK, driven by striking Phase 2 trial results and growing public interest in next-generation weight-loss medicines. Retatrutide is an investigational triple hormone receptor agonist developed by Eli Lilly that has not yet received MHRA or EMA approval. With no licensed UK supply route outside approved clinical trials, some individuals are turning to unregulated online sources, grey-market suppliers, and overseas compounding pharmacies. This article explains the current regulatory status of retatrutide, the routes people are using to access it, the serious risks involved, and the approved alternatives available through legitimate NHS and private channels.

What Is Retatrutide and Where Does It Currently Stand in the UK?

Retatrutide is an unlicensed investigational medicine with no MHRA or EMA approval; it cannot be legally prescribed or dispensed in the UK outside approved clinical trials, and NICE has issued no guidance on its use.

Retatrutide is an investigational weight-loss medicine developed by Eli Lilly. It is a triple hormone receptor agonist that simultaneously activates three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Preclinical and early clinical data suggest this triple mechanism may reduce appetite and support metabolic function, though direct head-to-head comparisons with approved agents in humans are not yet available, and claims of superior potency remain unproven at this stage.

As of the date of publication, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, nor has it been approved by the European Medicines Agency (EMA).^[6] It remains in clinical development, with Phase 3 trials ongoing as of mid-2025 (see ClinicalTrials.gov for current registered studies and their verification dates). Phase 2 trial data published in the New England Journal of Medicine in 2023 demonstrated substantial weight reduction — up to approximately 24% of body weight over 48 weeks — which generated considerable public and media interest.

Because retatrutide does not hold a UK marketing authorisation, it cannot be dispensed or sold through standard NHS or private pharmacy channels. While UK prescribers can in principle use unlicensed medicines in limited circumstances under their own responsibility, retatrutide currently has no sanctioned UK supply route outside approved clinical trials: it holds no marketing authorisation in any jurisdiction, and neither the Early Access to Medicines Scheme (EAMS) nor named-patient unlicensed supply applies, as those routes require either an active MHRA EAMS scientific opinion or a product authorised in another country from which a licensed import can be sourced. Neither condition is met for retatrutide at the time of publication. It is not listed in the British National Formulary (BNF), and NICE has not issued any guidance on its use. Any access outside of formally approved clinical trials therefore has no sanctioned UK pathway and carries important implications for patient safety.

How People Are Accessing Retatrutide at Present

People are accessing retatrutide through unregulated online suppliers, overseas compounding pharmacies, and social media networks; clinical trial enrolment via platforms such as NIHR Be Part of Research is the only lawful UK route.

Despite its unapproved status, there are reports — consistent with MHRA enforcement activity and alerts concerning unauthorised injectable weight-loss products — that some individuals are actively seeking and obtaining retatrutide through unofficial channels. Understanding how this is happening is important for both patients and clinicians.

The routes through which people are reportedly accessing retatrutide include:

• Online grey-market suppliers and overseas websites: A number of websites, often based outside the UK or EU, are selling retatrutide — sometimes labelled as a 'research chemical' — directly to consumers. These products are not subject to MHRA oversight and their quality, purity, and dosage accuracy cannot be verified. The MHRA has issued Drug Alerts and enforcement notices about falsified and unauthorised injectable weight-loss products, including counterfeit semaglutide (Ozempic), circulating in the UK market. The MHRA also provides guidance on the risks of buying medicines online and via social media (available at mhra.gov.uk).

• Compounding pharmacies abroad: Some individuals are ordering from countries where regulatory frameworks differ. Compounded versions of retatrutide hold no marketing authorisation in any jurisdiction (as of the date of publication) and cannot be assumed to match the formulation used in clinical trials; their safety and quality are unverifiable.

• Participation in clinical trials: The only lawful and medically supervised route to accessing retatrutide in the UK is through enrolment in an approved clinical trial. UK-based trials can be found via the NIHR's Be Part of Research platform (bepartofresearch.nihr.ac.uk), the ISRCTN registry (isrctn.com), and ClinicalTrials.gov for multinational studies. Eligibility criteria typically include specific BMI thresholds and health conditions.

• Social media and peer networks: Online communities focused on weight loss have become informal information-sharing hubs, with some members directing others towards unregulated suppliers.

Clinical trial participation is the only lawful and medically supervised means of accessing retatrutide in the UK at present. All other routes described above carry significant legal and health risks. Unauthorised supply of prescription-only medicines is illegal under the Human Medicines Regulations 2012.^[8][9] Importing prescription-only medicines for personal use without a valid prescription and through unlicensed channels may also contravene UK law; the MHRA's guidance on personal importation sets out the relevant restrictions.

The Risks of Obtaining Retatrutide Outside Clinical Trials

Obtaining retatrutide outside clinical trials risks counterfeit or contaminated products, an incompletely established adverse effect profile, no medical oversight, and potential legal consequences under the Human Medicines Regulations 2012.

Obtaining any unlicensed medicine outside of a regulated clinical trial environment carries serious risks, and retatrutide is no exception.

Product quality and safety: Medicines purchased from unregulated online suppliers or grey-market sources may be counterfeit, contaminated, or incorrectly dosed. Without MHRA oversight, there is no guarantee that what is labelled as retatrutide contains the active compound — or that it does not contain harmful adulterants. Non-sterile or mislabelled injectable products also carry a risk of localised or systemic infection, and errors in dosing or injection technique are more likely without clinical supervision.

Incompletely established adverse effect profile: Although Phase 2 trial data (Jastreboff et al., NEJM, 2023) provides some safety information, the full adverse effect profile of retatrutide has not yet been established through the complete Phase 3 programme. Side effects reported in trials include nausea, vomiting, diarrhoea, decreased appetite, and injection site reactions.^[1][2] Rarer or longer-term effects remain under investigation. Without medical supervision, adverse effects may go unrecognised or unmanaged.

No medical oversight: In a clinical trial, participants are closely monitored by healthcare professionals who can identify and respond to complications. Self-administering an unlicensed injectable medicine without this support significantly increases risk.

Legal implications: Unauthorised supply of prescription-only medicines is illegal in the UK. Importing unlicensed medicines for personal use through unlicensed channels may also contravene the Human Medicines Regulations 2012, and individuals should be aware of the potential legal consequences.

When to seek urgent help: If you experience any of the following after taking any unregulated product, seek urgent medical attention immediately — call 999 or go to your nearest A&E:

• Severe or persistent abdominal pain (which may indicate pancreatitis)

• Persistent vomiting or signs of dehydration (dizziness, very dark urine, inability to keep fluids down)

• Signs of a serious allergic reaction (swelling of the face, lips, or throat; difficulty breathing; rash)

For less urgent concerns, contact your GP or call NHS 111. If you suspect you have experienced a side effect from an unregulated product, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If you are taking part in a clinical trial, report any suspected side effects to the trial team or study sponsor as instructed at enrolment.

MHRA and NHS Guidance on Unapproved Weight Loss Medicines

The MHRA advises only using medicines prescribed by a registered UK clinician and dispensed by a GPhC-registered pharmacy; suspected unlicensed or counterfeit products should be reported via mhra.gov.uk.

The MHRA has issued repeated warnings about the dangers of purchasing unlicensed weight-loss medicines online. These warnings are particularly relevant in the context of injectable GLP-1 and related receptor agonists, a class that has seen a significant rise in falsified and substandard products circulating in the UK. The MHRA has published specific Drug Alerts and enforcement notices regarding counterfeit semaglutide (Ozempic) and other unauthorised GLP-1 products; these are available via the Drug Alerts section of mhra.gov.uk.

The MHRA advises the public to:

• Only use medicines that have been prescribed by a registered UK clinician and dispensed by a pharmacy registered with the General Pharmaceutical Council (GPhC). You can verify whether an online pharmacy is legitimately registered using the GPhC online register at pharmacyregulation.org.

• Check the electronic Medicines Compendium (emc) at medicines.org.uk for UK-authorised product information, including Summaries of Product Characteristics (SmPCs) and Patient Information Leaflets, to confirm whether a medicine is licensed in the UK.

• Be cautious of websites that do not require a prescription, offer unusually low prices, or cannot be verified on the GPhC register.

• Report suspected counterfeit or unlicensed medicines and suspected illegal sale of medicines to the MHRA via their 'report a problem with a medicine or medical device' page at mhra.gov.uk.

The NHS does not endorse, fund, or support access to retatrutide outside of approved research settings. NHS England's guidance on obesity pharmacotherapy is aligned with NICE technology appraisals, which currently cover only licensed medicines. Clinicians working within the NHS are not in a position to prescribe or recommend retatrutide to patients. Patients are encouraged to raise questions about emerging treatments with their GP or specialist rather than seeking unregulated alternatives independently.

What Approved Alternatives Are Available in the UK Right Now?

MHRA-approved and NICE-recommended options include semaglutide 2.4 mg (Wegovy) and tirzepatide (Mounjaro) for eligible adults within specialist weight management services, alongside orlistat and naltrexone/bupropion (Mysimba).

For individuals seeking effective, evidence-based pharmacological support for weight management in the UK, there are currently several MHRA-approved options available, some of which are also recommended by NICE.

Semaglutide 2.4 mg (Wegovy): A once-weekly injectable GLP-1 receptor agonist approved by the MHRA for chronic weight management. NICE recommended semaglutide 2.4 mg (TA875, 2023) for use within specialist Tier 3 weight management services in adults with a BMI of 35 kg/m² or above (or 32.5 kg/m² or above in people of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family background) with at least one weight-related comorbidity, or a BMI of 30 to 34.9 kg/m² (27.5 to 32.4 kg/m² for the same ethnic groups) in specific circumstances. NICE guidance specifies a maximum treatment duration of two years within the NHS. Access criteria and availability vary across NHS regions and Integrated Care Boards (ICBs). The emc SmPC for Wegovy is available at medicines.org.uk and provides full prescribing and safety information.

Tirzepatide (Mounjaro): A dual GIP and GLP-1 receptor agonist approved by the MHRA for weight management in adults.^[13][14] NICE has recommended tirzepatide for obesity (TA1026, 2024) within specialist weight management services for adults with a BMI of 35 kg/m² or above (or 32.^[15][16]5 kg/m² or above for the same ethnic groups as above) and at least one weight-related comorbidity, subject to a maximum treatment duration of two years. Local commissioning arrangements continue to evolve; readers should refer to the current NICE TA1026 recommendations and the emc SmPC for Mounjaro (available at medicines.org.uk) for the most up-to-date access criteria. Clinical trial data from the SURMOUNT programme demonstrated weight reductions of up to approximately 22% of body weight.^[17][18]

Orlistat: An orally administered option that works by inhibiting pancreatic lipase, reducing dietary fat absorption by approximately 30%.^[19] It is available on NHS prescription for adults with a BMI of 28 kg/m² or above (with risk factors) or 30 kg/m² or above, alongside dietary and lifestyle measures. It is also available over the counter as Alli (60 mg) for adults with a BMI of 28 kg/m² or above. Common side effects include oily or fatty stools and faecal urgency, particularly if dietary fat intake is high.

Naltrexone/bupropion (Mysimba): A licensed combination oral tablet that acts on the central nervous system to reduce appetite and food cravings. It is available via private prescription in the UK but is not routinely commissioned on the NHS and is not NICE-recommended for routine NHS use. Important contraindications include uncontrolled hypertension, a history of seizure disorders, and current or recent use of opioid medicines. Patients should review the full SmPC on the emc before use.

Patients should discuss eligibility for these treatments with their GP or a specialist obesity service. Referral pathways and criteria are set out in NICE guideline NG246 (Overweight and obesity: assessment and management), though waiting times and commissioning arrangements vary by ICB.

How to Speak to a UK Clinician About Emerging Obesity Treatments

The safest first step is to speak with your GP, who can assess eligibility for approved treatments, refer you to a specialist obesity service, and advise on legitimate clinical trial opportunities.

If you are interested in retatrutide or other emerging obesity treatments, the most appropriate and safest first step is to have an open, informed conversation with a registered UK healthcare professional. Clinicians are well placed to discuss the current evidence base, explain what is and is not yet available, and help you access appropriate care through legitimate channels.

Starting the conversation with your GP: Your GP can review your weight management history, assess your eligibility for currently approved treatments, and refer you to a specialist obesity service if appropriate. It is helpful to come prepared with questions and to be honest about any steps you may have already taken, including use of any unregulated products. GPs are bound by patient confidentiality and are there to support, not judge.

Specialist weight management services: NHS Tier 3 and Tier 4 obesity services provide multidisciplinary support including dietetic, psychological, and pharmacological input. These services are best placed to discuss emerging treatments and may have access to clinical trial opportunities. Referral criteria are outlined in NICE guideline NG246; waiting times and local pathways vary by region.

Clinical trial participation: If you are interested in accessing retatrutide through a legitimate route, ask your clinician about ongoing trials. You can also search for UK-based studies via the NIHR Be Part of Research platform (bepartofresearch.nihr.ac.uk), the ISRCTN registry (isrctn.com), or ClinicalTrials.gov for multinational trials. Eligibility criteria will apply.

Private clinicians: Some private obesity specialists may be more up to date with emerging research and can provide detailed guidance on the pipeline of treatments. Ensure any private clinician is registered with the General Medical Council (GMC) (gmc-uk.org) and that the provider is registered with the Care Quality Commission (CQC) (cqc.org.uk). Routine care should use MHRA-licensed medicines; UK clinicians may in limited circumstances use unlicensed medicines under their own responsibility, but this is the exception rather than the rule and does not apply where no lawful supply route exists.

Above all, patient safety must remain the priority. No potential benefit of an unapproved medicine outweighs the risks of accessing it through unregulated means.

Frequently Asked Questions